Status:
ACTIVE_NOT_RECRUITING
Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies
Lead Sponsor:
Karolinska Institutet
Conditions:
Prostate Cancer
Eligibility:
MALE
50-74 years
Phase:
NA
Brief Summary
The STHLM3-MRI trial is a study comparing traditional prostate cancer detection using PSA and systematic biopsies with the improved pipeline for prostate cancer detection using the STHLM3 test and tar...
Detailed Description
The overarching strategy of the STHLM3-MR/Fusion projects are to study an improved diagnostic pipeline including an improved blood-based test for identification of men with increased risk of prostate ...
Eligibility Criteria
Inclusion
- Permanent postal address in Stockholm
Exclusion
- • Severe illnesses such as metastatic cancers, severe cardio-vascular disease or dementia
- Contraindications for magnetic resonance imaging (MRI) eg pacemaker, magnetic cerebral clips, cochlear implants or severe claustrophobia.
Key Trial Info
Start Date :
April 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2030
Estimated Enrollment :
12750 Patients enrolled
Trial Details
Trial ID
NCT03377881
Start Date
April 4 2018
End Date
December 10 2030
Last Update
December 26 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
C-medical Odenplan Urology
Stockholm, Sweden
2
Capio St Görans Hospital
Stockholm, Sweden
3
Urologifocus
Stockholm, Sweden